Cardio Diagnostics (NASDAQ:CDIO) Posts Quarterly Earnings Results

Cardio Diagnostics (NASDAQ:CDIO) announced its quarterly earnings data on Friday. The company reported ($0.80) EPS for the quarter, Zacks reports. Cardio Diagnostics had a negative return on equity of 67.51% and a negative net margin of 39,674.18%.

Cardio Diagnostics Stock Down 38.6%

Cardio Diagnostics stock traded down $1.76 during midday trading on Friday, reaching $2.80. The company’s stock had a trading volume of 1,127,513 shares, compared to its average volume of 10,924,570. The company has a market cap of $5.12 million, a P/E ratio of -0.75 and a beta of 2.28. The business has a 50-day simple moving average of $2.68 and a 200-day simple moving average of $3.33. Cardio Diagnostics has a fifty-two week low of $0.97 and a fifty-two week high of $17.39.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Cardio Diagnostics in a research note on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has an average rating of “Sell”.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Cardio Diagnostics stock. Citadel Advisors LLC bought a new position in shares of Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 19,520 shares of the company’s stock, valued at approximately $79,000. Citadel Advisors LLC owned approximately 1.07% of Cardio Diagnostics as of its most recent filing with the SEC. 8.06% of the stock is currently owned by institutional investors and hedge funds.

Cardio Diagnostics Company Profile

Cardio Diagnostics Holdings, Inc develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc was founded in 2017 and is headquartered in Chicago, Illinois.